SMC5 and cancer: Furthermore, while the expression of the TIMELESS/TIPIN complex limits telomeric MiDAS, the activity of the SMC5/6 complex encourages telomeric MiDAS, further supporting the role inhibition of SMC5/6 in the development of a therapeutic approach for ALT cancers [76].